Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].

Enfermedades infecciosas y microbiologia clinica - 1 Dec 2006

Sirvent Elia, Ruiz Montserrat, Rodríguez Juan C, Royo Gloria

Abstract excerpt

INTRODUCTION: The objective of this study was to compare the activity of ciprofloxacin, levofloxacin, moxifloxacin, gatifloxacin and ofloxacin against Pseudomonas aeruginosa by determining the mutant prevention concentration (MPC). METHODS: Thirty-four clinical isolates of Pseudomonas aeruginosa causing nosocomial infection were studied. MPC values were determined using an inoculum of 10(10) cfu/mL on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aza Compounds
Share to Ciprofloxacin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluoroquinolones

Share to Levofloxacin

Share to Moxifloxacin

Share to Ofloxacin

Share to Pseudomonas Infections

Share to Quinolines

Source

Identifiers

PMID: 17194384
DOI: 10.1157/13095370

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].PMID 17194384Read ↗

[Resistant mutant prevention concentration of fluoroquinolones in clinical isolates of extended spectrum beta-lactamase (ESBL) producing and non-producing strains of Escherichia coli].Semantic proximity Read ↗

[Mutant prevention concentrations of fluoroquinolones for Staphylococcus aureus].Semantic proximity Read ↗

Mutant prevention concentrations of ciprofloxacin against urinary isolates of Escherichia coli and Klebsiella pneumoniae.Semantic proximity Read ↗

Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa.Semantic proximity Read ↗

[Mutant prevention concentrations of antibacterial agents to ocular pathogenic bacteria].Semantic proximity Read ↗

Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.Semantic proximity Read ↗

Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa.Semantic proximity Read ↗

Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis.Semantic proximity Read ↗

[The concentrations of fluoroquinolones in prevention of Staphylococcus epidermidis from mutant in ocular surface].Semantic proximity Read ↗

Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus.Semantic proximity Read ↗

Mutant prevention concentrations of levofloxacin, pazufloxacin and ciprofloxacin for A. baumannii and mutations in gyrA and parC genes.Semantic proximity Read ↗

Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.